This company has been marked as potentially delisted and may not be actively trading. Capstar Special Purpose Acquisition (CPSR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CPSR vs. RNA, AKRO, MRUS, PTGX, MOR, OGN, CPRX, CRNX, VKTX, and XENEShould you be buying Capstar Special Purpose Acquisition stock or one of its competitors? The main competitors of Capstar Special Purpose Acquisition include Avidity Biosciences (RNA), Akero Therapeutics (AKRO), Merus (MRUS), Protagonist Therapeutics (PTGX), MorphoSys (MOR), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "medical" sector. Capstar Special Purpose Acquisition vs. Avidity Biosciences Akero Therapeutics Merus Protagonist Therapeutics MorphoSys Organon & Co. Catalyst Pharmaceuticals Crinetics Pharmaceuticals Viking Therapeutics Xenon Pharmaceuticals Capstar Special Purpose Acquisition (NYSE:CPSR) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment. Which has stronger earnings & valuation, CPSR or RNA? Capstar Special Purpose Acquisition has higher earnings, but lower revenue than Avidity Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapstar Special Purpose AcquisitionN/AN/A-$15.30MN/AN/AAvidity Biosciences$10.90M294.10-$212.22M-$2.89-9.22 Does the MarketBeat Community favor CPSR or RNA? Avidity Biosciences received 168 more outperform votes than Capstar Special Purpose Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformCapstar Special Purpose AcquisitionN/AN/AAvidity BiosciencesOutperform Votes16869.14% Underperform Votes7530.86% Does the media refer more to CPSR or RNA? In the previous week, Avidity Biosciences had 12 more articles in the media than Capstar Special Purpose Acquisition. MarketBeat recorded 12 mentions for Avidity Biosciences and 0 mentions for Capstar Special Purpose Acquisition. Avidity Biosciences' average media sentiment score of 0.90 beat Capstar Special Purpose Acquisition's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Capstar Special Purpose Acquisition Neutral Avidity Biosciences Positive Which has more risk & volatility, CPSR or RNA? Capstar Special Purpose Acquisition has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Do analysts rate CPSR or RNA? Avidity Biosciences has a consensus price target of $66.69, suggesting a potential upside of 150.16%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Capstar Special Purpose Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstar Special Purpose Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CPSR or RNA more profitable? Capstar Special Purpose Acquisition has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,772.45%. Capstar Special Purpose Acquisition's return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Capstar Special Purpose AcquisitionN/A N/A N/A Avidity Biosciences -2,772.45%-27.66%-24.56% Do institutionals & insiders have more ownership in CPSR or RNA? 64.9% of Capstar Special Purpose Acquisition shares are owned by institutional investors. 3.7% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryAvidity Biosciences beats Capstar Special Purpose Acquisition on 9 of the 14 factors compared between the two stocks. Get Capstar Special Purpose Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for CPSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPSR vs. The Competition Export to ExcelMetricCapstar Special Purpose AcquisitionPharmaceutical Preparations IndustryMedical SectorNYSE ExchangeMarket Cap$808.34M$6.44B$5.29B$18.42BDividend YieldN/A3.23%5.12%4.21%P/E RatioN/A6.8821.7331.10Price / SalesN/A231.02379.1626.58Price / CashN/A65.6738.2217.54Price / Book-19.865.916.444.30Net Income-$15.30M$142.72M$3.21B$1.02B Capstar Special Purpose Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPSRCapstar Special Purpose AcquisitionN/A$23.43+0.0%N/A+258.7%$808.34MN/A0.002RNAAvidity Biosciences2.162 of 5 stars$26.68-0.9%$66.69+150.0%+13.2%$3.21B$10.90M-9.26190AKROAkero Therapeutics4.2779 of 5 stars$38.08+1.3%$76.29+100.3%+74.2%$3.03BN/A-10.1530Insider TradeMRUSMerus2.9726 of 5 stars$43.22+1.9%$85.31+97.4%+4.9%$2.99B$36.13M-10.9437PTGXProtagonist Therapeutics3.792 of 5 stars$46.95+4.3%$65.44+39.4%+81.0%$2.88B$434.43M17.65120Positive NewsHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730OGNOrganon & Co.4.794 of 5 stars$11.07-2.1%$20.60+86.2%-37.8%$2.85B$6.40B3.3210,000Short Interest ↓CPRXCatalyst Pharmaceuticals4.611 of 5 stars$23.23+1.9%$32.29+39.0%+40.8%$2.82B$491.73M19.6980Positive NewsCRNXCrinetics Pharmaceuticals3.6073 of 5 stars$29.66-0.4%$73.00+146.1%-30.9%$2.76B$1.04M-7.95210Positive NewsVKTXViking Therapeutics4.3614 of 5 stars$23.11-5.9%$89.75+288.4%-64.0%$2.59BN/A-23.1120Upcoming EarningsAnalyst ForecastOptions VolumeGap DownXENEXenon Pharmaceuticals2.7351 of 5 stars$33.03-1.2%$57.38+73.7%-15.6%$2.53B$9.43M-11.71210Analyst DowngradeOptions VolumeAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Avidity Biosciences Competitors Akero Therapeutics Competitors Merus Competitors Protagonist Therapeutics Competitors MorphoSys Competitors Organon & Co. Competitors Catalyst Pharmaceuticals Competitors Crinetics Pharmaceuticals Competitors Viking Therapeutics Competitors Xenon Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPSR) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstar Special Purpose Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstar Special Purpose Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CPSR Stock Free CPSR Stock Alerts